Taylor C M, Wallace J E, Cundy T, Kanis J A
Miner Electrolyte Metab. 1982 Jan;7(1):15-9.
Serum levels of the dihydroxylated metabolite of vitamin D3, 24,25-dihydroxycholecalciferol (24, 25(OH)2D3) were measured by competitive protein-binding assay in 2 anephric patients while undergoing therapy with 25-hydroxycholecalciferol (25(OH)D3) and, at a later date, vitamin D2, ergocalciferol. Whereas there was no increase in serum levels of 24, 25 (OH)2D3 when the patients were treated with 25 (OH)D3, a significant increase was apparently seen when vitamin D2 was given. These results suggest that a metabolite of vitamin D2, non-renal in origin, may be interfering in the assay for 24, 25 (OH)2D3. The different levels of serum 24, 25 (OH)2D3 in anephric man found by various groups of workers are explained by these results.
采用竞争性蛋白结合分析法，对2例无肾患者在接受25-羟胆钙化醇（25(OH)D3）治疗期间以及之后接受维生素D2（麦角钙化醇）治疗时，测定其血清中维生素D3的二羟基代谢产物24,25-二羟胆钙化醇（24,25(OH)2D3）的水平。当患者接受25(OH)D3治疗时，血清24,25(OH)2D3水平未升高，而给予维生素D2时，血清24,25(OH)2D3水平明显升高。这些结果表明，维生素D2的一种非肾脏来源的代谢产物可能干扰了24,25(OH)2D3的测定。不同研究小组在无肾男性中发现的血清24,25(OH)2D3水平差异可由这些结果来解释。
